Group 1 - The National Market Supervision Administration has approved the release of the "Guidelines for the Management of Campus Catering Service Enterprises," which will be implemented on December 1, 2025, marking the first national standard for campus catering services [1] - The guidelines require campus catering service companies to conduct comprehensive testing of bulk food ingredients and provide standardized guidance for recipe and raw material management, processing, preparation, and distribution, creating new market opportunities for the food safety testing industry [1] - EasyBio, a company specializing in rapid testing technology, has developed comprehensive testing solutions covering various stages from feed, breeding, production, processing, circulation, to retail, ensuring food safety from source to end [1] Group 2 - EasyBio has recently launched efficient water quality testing solutions, including rapid testing paper for coliform bacteria and an integrated portable multi-parameter water quality testing system, to ensure water safety [2] - The company is deepening cooperation with local government departments, including establishing a quality safety testing service center for agricultural and livestock products in collaboration with the Ordos Municipal Agricultural and Animal Husbandry Bureau [2] - A partnership is being formed to build the "Ordos Agricultural and Animal Husbandry Bay Area Base," facilitating cross-regional industrial collaboration [2] Group 3 - EasyBio signed a cooperation agreement with Denmark's Chr. Hansen in April, setting a global sales target of €73.0577 million (approximately 601 million RMB) for the period from 2025 to 2029, with 2025 accounting for 42.18% of the company's 2024 revenue [3] - The partnership allows Chr. Hansen to exclusively sell, distribute, and promote EasyBio's products globally, including tests for antibiotic residues in milk and aflatoxin M1 screening [3] - EasyBio is also entering the pet economy sector by introducing infectious disease testing products to pet hospitals, although it clarified that it does not currently involve testing for the chikungunya virus [3]

Core Viewpoint - The collaboration between EasyBio and Chr. Hansen marks a significant step in the company's internationalization strategy, with a sales target of €73.06 million (over 600 million RMB) from 2025 to 2029, which is expected to positively impact the company's future performance and market presence [1][2][6]. Group 1: Contract Details - EasyBio has signed a cooperation agreement with Chr. Hansen, setting a total sales target of €73.06 million for the period from 2025 to 2029, with the first year's target accounting for approximately 42.18% of the company's 2024 revenue [1][2]. - The sales targets are structured to grow by more than 10% in the first year and 12% in subsequent years, with annual targets increasing from approximately 95 million RMB in 2025 to nearly 150 million RMB in 2029 [2]. - The contract allows Chr. Hansen exclusive rights to sell and promote EasyBio's products globally, excluding specific countries, covering various testing products related to food safety [2][4]. Group 2: Strategic Importance - The partnership is a major breakthrough in EasyBio's internationalization strategy, which has been a key driver of the company's performance since 2023 [2]. - The collaboration will utilize a dual-brand approach, enhancing EasyBio's market penetration in the global dairy product sector while leveraging Chr. Hansen's brand influence [4]. - EasyBio aims to expand its market reach and product offerings beyond dairy, exploring opportunities in various sectors such as food, agriculture, and pharmaceuticals, supported by Chr. Hansen's and Novonesis's expertise [5]. Group 3: Market Impact - The collaboration is expected to enhance EasyBio's core competitiveness and market influence, contributing to sustainable business growth [6]. - EasyBio's international sales have shown significant growth, with overseas revenue increasing by 15.92% in 2024, reaching approximately 93.33 million RMB, and the proportion of overseas revenue rising from 31.68% in 2023 to 41.62% in 2024 [5].

Core Viewpoint - The company has signed a Partnership and Distribution Agreement with Chr.Hansen A/S, targeting a total sales goal of €73.0577 million (approximately ¥601 million) for the years 2025-2029, which is expected to positively impact the company's financial status and operational performance [1] Group 1: Agreement Details - The sales target for 2025 accounts for approximately 42.18% of the company's audited revenue for 2024 [1] - The agreement allows Chr.Hansen exclusive rights to sell, distribute, and promote the company's products in designated regions [1] - The contract will be effective from June 16, 2025, and will last for five years [1] Group 2: Product Focus - The main products involved in the agreement include antibiotic residue screening tests for milk, aflatoxin M1 screening and quantitative tests, melamine, and whey adulteration tests [1] Group 3: Strategic Impact - The partnership is expected to enhance the company's core competitiveness and market influence [1]